Gene · 6421
NIH grants1,450
NIH grants whose papers are about the gene, through NIH's grant-paper links.
481 to 500 of 1,450
Download this page as JSON| Grant | Title | SFPQ papers | Newest fiscal year |
|---|---|---|---|
| R01NS104219 | Determining How Defective Nucleo-Cytoplasmic Trafficking Leads To Neurodegeneration In C9orf72-Related ALS And FTD | 1 | 2022 |
| R01NS105756 | An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD | 1 | 2022 |
| R01NS107131 | Fragile X-associated tremor/ataxia syndrome (FXTAS) pathology and anatomy: imaging and clinical correlates | 1 | 2022 |
| R01NS107442 | Mechanisms of Axon Pathology in ALS | 1 | 2022 |
| R01NS107488 | Mechanistic insights into neurodegeneration in Huntington's disease using patient-derived neurons through direct conversion of fibroblasts | 1 | 2022 |
| R01NS109147 | The role of NONO in TAZ-driven glioma malignant transformation | 1 | 2022 |
| R01NS109588 | Role of CaMKII-alpha ubiquitination in ischemic stroke | 1 | 2022 |
| R03HL150412 | Computational Prioritization of Coding and Non-Coding Variants in Congenital Heart Disease | 1 | 2022 |
| R21AG079609 | Engineering therapeutic TRIM11 disaggregases for Alzheimer's Disease-Related Dementias (ADRDs) | 1 | 2022 |
| R21CA262991 | Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer | 1 | 2022 |
| R21CA263264 | Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer | 1 | 2022 |
| R21HD104071 | A new animal model for investigating the invasive trophoblast lineage | 1 | 2022 |
| R25GM060665 | RISE Program at Hunter College CUNY | 1 | 2022 |
| R25GM090084 | VCU Initiative for Maximizing Student Development Program (IMSD) | 1 | 2022 |
| R35GM126949 | Evolution and application of proximity protein labeling | 1 | 2022 |
| R56DK133258 | Targeting splicing in myelodysplasia through GSK-3 | 1 | 2022 |
| SC3GM131971 | Development of PARP-Isoform Selective Inhibitory Chemical Probes | 1 | 2022 |
| T32AI106677 | Basic Training at the Intersection of Innate and Adaptive Immunity in Disease | 1 | 2022 |
| T32GM007170 | Medical Scientist Training Program | 1 | 2022 |
| T32GM007288 | Medical Scientist Training Program | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6421/grants?page=25